OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -2.62%184.19M | 60.73%54.19M | -11.36%44.27M | -19.27%42.5M | -18.19%43.24M | -26.41%189.14M | -55.38%33.71M | -12.89%49.94M | -18.03%52.64M | -11.80%52.86M |
Operating revenue | -6.57%170.53M | 34.40%47.07M | -11.60%40.5M | -18.32%41.5M | -18.73%41.47M | -27.17%182.52M | -52.54%35.02M | -17.72%45.81M | -18.84%50.8M | -12.86%51.02M |
Cost of revenue | -1.41%98.29M | 103.14%32.91M | -5.91%23.35M | -27.44%21.56M | -29.33%20.47M | -33.59%99.69M | -64.36%16.2M | -25.93%24.82M | -20.59%29.71M | -14.13%28.96M |
Gross profit | -3.97%85.9M | 21.49%21.28M | -16.73%20.91M | -8.68%20.94M | -4.69%22.78M | -16.32%89.45M | -41.79%17.51M | 5.47%25.12M | -14.45%22.93M | -8.79%23.9M |
Operating expense | -10.35%22.29M | -25.96%5.77M | -8.41%5.59M | -9.58%4.91M | 8.73%6.03M | -13.91%24.87M | 1.76%7.79M | -12.22%6.1M | -14.40%5.43M | -30.14%5.54M |
Selling and administrative expenses | -10.35%22.29M | -25.96%5.77M | -8.41%5.59M | -9.58%4.91M | 8.73%6.03M | -13.91%24.87M | 1.76%7.79M | -12.22%6.1M | -14.40%5.43M | -30.14%5.54M |
-Selling and marketing expense | -258.70%-930K | -86.58%75K | -9,400.00%-475K | -567.00%-667K | 5.34%138K | -55.44%586K | 48.67%559K | -102.21%-5K | -122.78%-100K | -52.36%131K |
-General and administrative expense | -4.35%23.22M | -21.28%5.69M | -0.70%6.07M | 0.85%5.57M | 8.81%5.89M | -11.93%24.28M | -0.66%7.23M | -9.20%6.11M | -6.34%5.53M | -29.34%5.41M |
Operating profit | -1.51%63.61M | 59.53%15.51M | -19.41%15.32M | -8.40%16.03M | -8.74%16.75M | -17.22%64.59M | -56.66%9.72M | 12.76%19.01M | -14.47%17.5M | 0.48%18.35M |
Net non-operating interest income expense | -6.85%1.95M | -35.59%362K | -139.10%-192K | 74.25%751K | 69.87%1.03M | -18.62%2.09M | -13.14%562K | -6.12%491K | -28.17%431K | -24.22%604K |
Non-operating interest income | -12.72%2.64M | -59.62%365K | ---- | 57.51%986K | 87.34%1.3M | 2.62%3.02M | 29.89%904K | 29.95%794K | -20.05%626K | -18.52%695K |
Non-operating interest expense | -25.91%689K | -99.12%3K | -36.63%192K | 20.51%235K | 203.30%276K | 148.00%930K | 597.96%342K | 244.32%303K | 6.56%195K | 62.50%91K |
Other net income (expense) | 408.83%10.48M | 114.09%2.54M | 11,432.43%4.19M | 1,796.23%3.02M | -2.12%737K | 31.80%2.06M | 52.90%1.19M | -119.89%-37K | 835.29%159K | 28.50%753K |
Other non- operating income (expenses) | 408.83%10.48M | 114.09%2.54M | 11,432.43%4.19M | 1,796.23%3.02M | -2.12%737K | 31.80%2.06M | 52.90%1.19M | -119.89%-37K | 835.29%159K | 28.50%753K |
Income before tax | 10.62%76.04M | 60.50%18.41M | -0.73%19.33M | 9.43%19.8M | -6.08%18.51M | -16.33%68.74M | -51.92%11.47M | 10.80%19.47M | -14.17%18.09M | 0.31%19.71M |
Income tax | 0.84%14.4M | -11.32%3.89M | 4.20%3.52M | 17.49%3.61M | -1.80%3.37M | -0.69%14.28M | 5.43%4.39M | 19.18%3.38M | -19.55%3.07M | -3.46%3.44M |
Net income | 13.19%61.64M | 105.07%14.51M | -1.77%15.8M | 7.78%16.19M | -6.98%15.14M | -19.64%54.46M | -64.05%7.08M | 9.18%16.09M | -12.98%15.02M | 1.14%16.28M |
Net income continuous Operations | 13.19%61.64M | 105.07%14.51M | -1.77%15.8M | 7.78%16.19M | -6.98%15.14M | -19.64%54.46M | -64.05%7.08M | 9.18%16.09M | -12.98%15.02M | 1.14%16.28M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 13.19%61.64M | 105.07%14.51M | -1.77%15.8M | 7.78%16.19M | -6.98%15.14M | -19.64%54.46M | -64.05%7.08M | 9.18%16.09M | -12.98%15.02M | 1.14%16.28M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 13.19%61.64M | 105.07%14.51M | -1.77%15.8M | 7.78%16.19M | -6.98%15.14M | -19.64%54.46M | -64.05%7.08M | 9.18%16.09M | -12.98%15.02M | 1.14%16.28M |
Basic earnings per share | 14.35%2.55 | 110.34%0.61 | -1.52%0.65 | 8.06%0.67 | -7.46%0.62 | -19.78%2.23 | -64.20%0.29 | 10.00%0.66 | -12.68%0.62 | 1.52%0.67 |
Diluted earnings per share | 14.29%2.48 | 107.14%0.58 | 0.00%0.64 | 8.33%0.65 | -7.69%0.6 | -20.80%2.17 | -65.43%0.28 | 10.34%0.64 | -13.04%0.6 | 0.00%0.65 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |